Related references
Note: Only part of the references are listed.Risk of Metabolic Complications in Kidney Transplantation After Conversion to mTOR Inhibitor: A Systematic Review and Meta-Analysis
N. Murakami et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients
W. H. Lim et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
mTOR inhibitor-associated proteinuria in kidney transplant recipients
Fritz Diekmann et al.
TRANSPLANTATION REVIEWS (2012)
Posttransplantation Proteinuria: An Approach to Diagnosis and Management
M. Khaled Shamseddin et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial
Matthew R. Weir et al.
KIDNEY INTERNATIONAL (2011)
Proteinuria after conversion to sirolimus in kidney transplant recipients: impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists
Christian Marx et al.
CLINICAL TRANSPLANTATION (2010)
Relation Between Kidney Function, Proteinuria, and Adverse Outcomes
Brenda R. Hemmelgarn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway
Melinda Oroszlan et al.
TRANSPLANT IMMUNOLOGY (2010)
Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy
Alieu B. Amara et al.
TRANSPLANTATION (2010)
Significance and Management of Proteinuria in Kidney Transplant Recipients
Hatem Amer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Sirolimus interacts with pathways essential for podocyte integrity
Emmanuel Letavernier et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
Francesco P. Schena et al.
TRANSPLANTATION (2009)
Clinical Implications of Proteinuria in Renal Transplant Recipients Switching to Rapamycin for Chronic Allograft Dysfunction
M. J. Gutierrez et al.
TRANSPLANTATION PROCEEDINGS (2009)
Conversion to Sirolimus for Chronic Allograft Nephropathy and Calcineurin Inhibitor Toxicity and the Adverse Effects of Sirolimus After Conversion
B. Sayin et al.
TRANSPLANTATION PROCEEDINGS (2009)
Mechanisms and management of proteinuria in kidney transplant patients
Azemi A. Barama
DRUGS (2008)
Proteinuria after kidney transplantation, relationship to allograft histology and survival
H. Amer et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction
Juan Carlos Ruiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation
Georg Heinze et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Proteinuria following a switch from calcineurin inhibitors to sirolimus
E Letavernier et al.
TRANSPLANTATION (2005)
Post-transplantation proteinuria and sirolimus
H Izzedine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
